



### 17:00 - 17:10 Welcome Key Note

Shaheenah Dawood, UAE

### 17:12 - 19:25 Session 1

Chair: Faraz Khan, UAE

17:12 - 17:32 In the era of IO dual immunotherapy in the management of front line NSCLC **Supported by BMS**

Fathi Al Azribi, UAE

17:35 - 17:55 Immunotherapy updates in breast cancer **Supported by Roche**

Peter Schmid, UK

17:57 - 18:12 Immunotherapy cases in breast cancer

Hamdy A. Azim, Egypt

18:14 - 18:29 Immunotherapy updates in GI malignancies

Axel Grothey, USA

18:31 - 18:46 Immunotherapy updates in GU malignancies

Deborah Mukherji, Lebanon

18:48 - 19:03 Immunotherapy updates in lung cancer

Sanjay Popat, UK

19:05 - 19:25 Case Studies in first line management of NSCLC

Christan Rolfo, USA

19:25 - 19:40 Break ☕

### 19:40 - 20:34 Session 2

Chair: Nouri Bennini, UAE

19:40 - 20:00 Updates on role of checkpoint inhibitors in classical Hodgkin Lymphoma

Pier Luigi Zinzani, Italy

20:02 - 20:17 Defining the role of Dual immunotherapy approaches in solid malignancies

Tobias Arkenau, UK

20:19 - 20:34 Challenging case discussion sessions highlighting management of toxicity related to immunotherapy

Mohsen Mokhtar, Egypt

### 20:36 - 21:06 Panel discussion

Moderator: Shaheenah Dawood, UAE

Panellist: Hamdy A. Azim, Egypt | Tobias Arkenau, UK | Mohsen Mokhtar, Egypt  
Sanjay Popat, UK | Deborah Mukherji, Lebanon | Axel Grothey, USA  
Fathi Al Azribi, UAE | Abdulrahman Zar, Qatar | Ikram Burney, Oman  
Muath Nassar, Kuwait | Peter Schmid, UK

### 21:08 - 21:15 Closing Remark

Shaheenah Dawood